Sugi Predict

Sugi Predict / Compounds / SCHEMBL5312822

SCHEMBL5312822

SCHEMBL5312822

CC(=O)CCCNC(=O)OC(C)(C)C

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.62
▸ MEN1 O00255 1/20 0.59
▸ GAA P10253 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ MAOA P21397 1/20 0.54
▸ MAOB P27338 1/20 0.54
▸ CA1 P00915 10/20 0.51
▸ CA2 P00918 10/20 0.51
▸ CA12 O43570 6/20 0.51
▸ CA9 Q16790 6/20 0.51
▸ CYP3A4 P08684 1/20 0.45
▸ EPHX1 P07099 1/20 0.44
▸ HTT P42858 1/20 0.43
▸ STK17B O94768 1/20 0.43
▸ STK17A Q9UEE5 1/20 0.43
▸ CAPN1 P07384 1/20 0.43
▸ SIGMAR1 Q99720 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3219136 0.94 TDP1 (0.66) TDP1MEN1GAAKMT2AMAOA
SCHEMBL7911588 0.93 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL3209829 0.93 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL17483577 0.93 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL19243362 0.93 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL16671924 0.93 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL4001822 0.88 TDP1 (0.56) TDP1MEN1GAAKMT2AMAOA
SCHEMBL569251 0.86 TDP1 (0.74) TDP1MEN1GAAKMT2AMAOA
SCHEMBL3020258 0.86 TDP1 (0.81) TDP1MEN1GAAKMT2AMAOA
SCHEMBL27272531 0.85 TDP1 (0.55) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250145632-A1 Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine INSILICO MEDICINE IP LIMITED (HK) 2025-05-08 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 — — US disclosed
EP-4455132-A1 PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE Insilico Medicine IP Limited (HK) 2024-10-30 — — EP disclosed
US-20240317777-A1 NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-09-26 — — US disclosed
WO-2024178335-A2 NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS ACCUTAR BIOTECHNOLOGY, INC. (US) 2024-08-29 — — WO disclosed
EP-1040098-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (a New Jersey corp.) (US) 2000-10-04 — — EP disclosed
US-6090944-A Alkanoic acid derivatives as αv integrin receptor antagonists MERCK & CO., INC. (US) 2000-07-18 — — US disclosed
US-6048861-A OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS MERCK & CO., INC. (US) 2000-04-11 — — US disclosed
WO-2000009503-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2000-02-24 — — WO disclosed
WO-1999031061-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 — — WO disclosed
CN-1038511-C Imidazopyridine MERCK PATENT GMBH (DE) 1998-05-27 — — CN disclosed
EP-0796855-A1 Inhibitors of bone resorption and vitronectin receptor antagonists HOECHST AKTIENGESELLSCHAFT (DE) 1997-09-24 — — EP disclosed
CN-1129702-A Imidazopyridines MERCK PATENT GMBH (DE) 1996-08-28 — — CN disclosed
CN-1109057-A Imidazopyridazine MERCK PATENT GMBH (DE) 1995-09-27 — — CN disclosed
CN-1082545-A Imidazopyridine MERCK PATENT GMBH (DE) 1994-02-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TDP1 236/4885MEN1 4055/4885GAA 1234/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TDP1 236/4885MEN1 4055/4885GAA 1234/4885
US-20250145632-A1 Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine DPYD, TYMP, NUDT1 TDP1 1017/4885MEN1 1052/4885GAA 1949/4885
US-20240317777-A1 NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK20, CDK3 TDP1 493/4885MEN1 1719/4885GAA 2894/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TDP1 236/4885MEN1 4055/4885GAA 1234/4885
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 TDP1 1168/4885MEN1 1847/4885GAA 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.